Scopus
YÖKSİS Eşleşti
Unilateral Acute Iris Transillumination Syndrome following Uneventful Phacoemulsification Surgery with Intracameral Moxifloxacin
Ocular Immunology and Inflammation · Ocak 2022
YÖKSİS Kayıtları
Unilateral Acute Iris Transillumination Syndrome following Uneventful Phacoemulsification Surgery with Intracameral Moxifloxacin
Ocular Immunology and Inflammation · 2022 SCI
PROFESÖR ŞABAN GÖNÜL →
Unilateral Acute Iris Transillumination Syndrome following Uneventful Phacoemulsification Surgery with Intracameral Moxifloxacin
OCULAR IMMUNOLOGY AND INFLAMMATION · 2021 SCI-Expanded
PROFESÖR ŞABAN GÖNÜL →
Makale Bilgileri
DergiOcular Immunology and Inflammation
Yayın TarihiOcak 2022
Cilt / Sayfa30 · 1984-1987
Scopus ID2-s2.0-85106344151
Özet
Purpose: We report a case of unilateral acute iris transillumination (AIT) and iris sphincter paralysis in a 63-year-old male undergone uneventful phacoemulsification surgery with intracameral moxifloxacin (ICM). Case presentation: This is a case of AIT with no history of viral disease or use of systemic fluoroquinolone but an association with ICM after uneventful phacoemulsification. The clinical features of the affected eye are perfectly similar to what has been described in BAIT and hence we consider that unilateral AIT and BAIT share the same etiopathogenesis. At the end of the phacoemulsification, the patient received 0.15 ml of 5mg/ml moxifloxacin, which is notably higher than the dose that is commonly used for ICM. This may have caused the patient to develop BAIT-like syndrome after the ICM. Conclusion: 0.1 ml of 5mg/ml moxifloxacin or less should be used to reduce the risk of occurrences of this toxic effect caused by ICM.
Yazarlar (2)
1
Şaban Gönül
2
Serhat Eker
ORCID: 0000-0003-4107-7402
Anahtar Kelimeler
Bilateral acute depigmentation of the iris
Bilateral acute iris transillumination
Endophthalmitis prophylaxis
Intracameral moxifloxacin
Toxic effect
Kurumlar
Selçuk Tip Fakültesi
Konya Turkey
Metrikler
6
Atıf
2
Yazar
5
Anahtar Kelime